Competition in the diabetes treatment market is expected to heat up again next month. Following the patent expiry of the SGLT-2 inhibitor class drug Forxiga, which stirred the market in the first half of the year, the patent of Januvia, the leading DPP-4 inhibitor class drug, is set to expire next month.

Accordingly, a large number of same-ingredient generics and salt-modified versions of Januvia will enter the market in line with its patent expiry date, September 2.

According to the industry on the 18th, Januvia's substance patent expires on the 1st of next month, and generic companies have applied for reimbursement of their latecomers accordingly.

Januvia generic